Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 5
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Integrative methylome-transcriptome analysis unravels cancer cell vulnerabilities in infant MLL-rearranged B cell acute lymphoblastic leukemia

  • Tejedor, Juan Ramón
  • Bueno, Clara
  • Vinyoles, Meritxell
  • Petazzi, Paolo
  • Agraz-Doblas, Antonio
  • Cobo, Isabel
  • Torres-Ruiz, Raúl
  • Bayón, Gustavo F.
  • Pérez, Raúl F.
  • López-Tamargo, Sara
  • Gutiérrez-Agüera, Francisco
  • Santamarina-Ojeda, Pablo
  • Ramírez-Orellana, Manuel
  • Bardini, Michela
  • Cazzaniga, Giovanni
  • Ballerini, Paola
  • Schneider, Paulina
  • Stam, Ronald W.
  • Varela, Ignacio
  • Fraga, Mario F.
  • Fernández, Agustín F.
  • Menéndez, Pablo
B cell acute lymphoblastic leukemia (B-ALL) is the most common childhood cancer. As predicted by its prenatal origin, infant B-ALL (iB-ALL) shows an exceptionally silent DNA mutational landscape, suggesting that alternative epigenetic mechanisms may substantially contribute to its leukemogenesis. Here, we have integrated genome-wide DNA methylome and transcriptome data from 69 patients with de novo MLL-rearranged leukemia (MLLr) and non-MLLr iB-ALL leukemia uniformly treated according to the Interfant-99/06 protocol. iB-ALL methylome signatures display a plethora of common and specific alterations associated with chromatin states related to enhancer and transcriptional control in normal hematopoietic cells. DNA methylation, gene expression, and gene coexpression network analyses segregated MLLr away from non-MLLr iB-ALL and identified a coordinated and enriched expression of the AP-1 complex members FOS and JUN and RUNX factors in MLLr iB-ALL, consistent with the significant enrichment of hypomethylated CpGs in these genes. Integrative methylome-transcriptome analysis identified consistent cancer cell vulnerabilities, revealed a robust iB-ALL–specific gene expression–correlating dmCpG signature, and confirmed an epigenetic control of AP-1 and RUNX members in reshaping the molecular network of MLLr iB-ALL. Finally, pharmacological inhibition or functional ablation of AP-1 dramatically impaired MLLr-leukemic growth in vitro and in vivo using MLLr-iB-ALL patient–derived xenografts, providing rationale for new therapeutic avenues in MLLr-iB-ALL., We thank CERCA/Generalitat de Catalunya (SGR180) and Fundació Josep Carreras-Obra Social la Caixa for their institutional support. Financial support for this work was obtained from the European Research Council (CoG-2014-646903 and PoC-2018-811220 to PM), the Spanish Ministry of Economy and Competitiveness (SAF-2019-108160-R and SAF2016-76758-R to PM and IV, respectively), the Spanish Association against cancer (AECC-CI-2015 and PROYE18061FERN to CB and MFF), the Fundación Uno entre Cienmil (to PM), the Health Institute Carlos III (ISCIII/FEDER, PI17/01028, PI15/00892, PI18/01527 to CB and AFF/MFF, respectively). We also acknowledge the Plan de Ciencia, Tecnología e Innovación from the Asturias Government cofunding 2018–2022/FEDER (IDI/2018/146to MFF). MFF also acknowledges funding from Fundación General CSIC (0348_CIE_6_E). PM also acknowledges financial support from Fundación Leo Messi. JRT and MV are supported by Juan de la Cierva fellowships by the Spanish Ministry of Science and Innovation (FJCI-2015-26965, IJC2018-36825-I, IJCI-2017-3317) and IUOPA-ISPA-FINBA (The IUOPA is supported by the Obra Social Cajastur-Liberbank, Spain). RTR is supported by a fellowship from the AECC scientific foundation. RFP and PSO are supported by the Severo Ochoa program (BP17-114 and BP17-165, respectively)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Enhanced detection of viral RNA species using fokI-assisted digestion of DNA duplexes and DNA/RNA hybrids

  • Tejedor, Juan Ramón
  • Martín, Gabriel
  • Roberti, Annalisa
  • Mangas, Cristina
  • Santamarina-Ojeda, Pablo
  • Pérez, Raúl F.
  • López, Virginia
  • Urdinguio, Rocío G.
  • Alba-Linares, Juan J.
  • Peñarroya, Alfonso
  • Álvarez-Argüelles, Marta E.
  • Boga, José A.
  • Fernández, Agustín F.
  • Rojo-Alba, Susana
  • Fraga, Mario F.
The accurate detection of nucleic acids from certain biological pathogens is critical for the diagnosis of human diseases. However, amplified detection of RNA molecules from a complex sample by direct detection of RNA/DNA hybrids remains a challenge. Here, we show that type IIS endonuclease FokI is able to digest DNA duplexes and DNA/RNA hybrids when assisted by a dumbbell-like fluorescent sensing oligonucleotide. As proof of concept, we designed a battery of sensing oligonucleotides against specific regions of the SARS-CoV-2 genome and interrogated the role of FokI relaxation as a potential nicking enzyme for fluorescence signal amplification. FokI-assisted digestion of SARS-CoV-2 probes increases the detection signal of ssDNA and RNA molecules and decreases the limit of detection more than 3.5-fold as compared to conventional molecular beacon approaches. This cleavage reaction is highly specific to its target molecules, and no detection of other highly related B-coronaviruses was observed in the presence of complex RNA mixtures. In addition, the FokI-assisted reaction has a high multiplexing potential, as the combined detection of different viral RNAs, including different SARS-CoV-2 variants, was achieved in the presence of multiple combinations of fluorophores and sensing oligonucleotides. When combined with isothermal rolling circle amplification technologies, FokI-assisted digestion reduced the detection time of SARS-CoV-2 in COVID-19-positive human samples with adequate sensitivity and specificity compared to conventional reverse transcription polymerase chain reaction approaches, highlighting the potential of FokI-assisted signal amplification as a valuable sensing mechanism for the detection of human pathogens., Funding was provided by the ISCIII (COV00624 to J.R.T. andM.F.F., PI18/01527 and PI21/01067 to M.F.F.), CSIC (202020E092 to M.F.F), the European Commission NextGenerationEU, through CSIC’s Global Health Platform (PTI Salud Global) and the Spanish Ministry of Science and Innovation through the Recovery, Transformation and Resilience Plan (GL2021-03-39 and GL2021-03-040), the PCTI from the Asturias Government, co-funded by 2018−2022/FEDER (IDI/2018/146 to M.F.F.), the AECC (PROYE18061FERN to M.F.F), ISPA-Janssen (048-Intramural Nov-Tevar to J.R.T.) and the IUOPA. J.R.T is supported by a JdC fellowship from the Spanish Ministry of Science and Innovation (IJC2018-36825-I). R.F.P. and P.S.O. are supported by the Severo Ochoa program (BP17-114 and BP17-165). A.P. is supported by the PFIS program (ISCIII, FI19/ 00085). J.J.A.L. is supported by the AECC fellowship. C.M. and V.L. are supported by IUOPA, and R.G.U. is supported by CIBERER., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Aging and cancer epigenetics: Where do the paths fork?

  • Pérez, Raúl F.
  • Tejedor, Juan Ramón
  • Fernández, Agustín F.
  • Fraga, Mario F.
Aging and cancer are clearly associated processes, at both the epidemiological and molecular level. Epigenetic mechanisms are good candidates to explain the molecular links between the two phenomena, but recent reports have also revealed considerable differences, particularly regarding the loss of DNA methylation in the two processes. The large-scale generation and availability of genome-wide epigenetic data now permits systematic studies to be undertaken which may help clarify the similarities and differences between aging and cancer epigenetic alterations. In addition, the development of epigenetic clocks provides a new dimension in which to investigate diseases at the molecular level. Here, we examine current and future questions about the roles of DNA methylation mechanisms as causal factors in the processes of aging and cancer so that we may better understand if and how aging-associated epigenetic alterations lead to tumorigenesis. It seems certain that comprehending the molecular mechanisms underlying epigenetic clocks, especially with regard to somatic stem cell aging, combined with applying single-cell epigenetic-age profiling technologies to aging and cancer cohorts, and the integration of existing and upcoming epigenetic evidence within the genetic damage models of aging will prove to be crucial to improving understanding of these two interrelated phenomena., Asturias Government (PCTI) cofunding 2018-2022/ FEDER, Grant/Award Number: IDI/2018/146 and BP17-114; Centro de Investigación Biomédica en Red de Enfermedades Raras CIBERER; Fundación Bancaria Caja de Ahorros de Asturias; Fundación Científica Asociación Española Contra el Cáncer, Grant/Award Number: PROYE18061FERN; Fundación General CSIC, Grant/Award Number: 0348_CIE_6_E; Instituto de Salud Carlos III, Grant/Award Number: PI21/01067; Ministerio de Ciencia e Innovación, Grant/ Award Number: IJC2018-36825- I and SGL2021-03- 039/ 40
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Maternal obesity and gestational diabetes are associated with DNA methylation alterations in the offspring throughout the first year of life

  • Alba-Linares, Juan J.
  • Fernández-Pérez, Raúl
  • Ponce-Zanon, Francisco
  • García-Carbonell, Nuria
  • Gómez-Zafra, Rafael
  • Fraga, Mario F.
  • Lurbe, Empar
ESH 2022 Annual Meeting: June 17-20, Athens (Greece)., [Objective]: Obesity is a chronic metabolic disease of increasing prevalence and health importance in modern societies, which represents an added risk for the development of multiple pathologies. Moreover, epidemiological studies have shown how maternal obesity or gestational diabetes during pregnancy constitutes an important risk factor related to the appearance of cardiovascular and metabolic diseases in the offspring. Furthermore, this period of life is especially sensitive to extrinsic and intrinsic influence, so epigenetic remodelling may help explain the molecular mechanisms that underlie epidemiological findings. The main objective of this work was to determine the DNA methylation landscape of children born to mothers with obesity and gestational diabetes across their first year of life., [Design and method]: We have characterized the methylome of blood samples from a paediatric cohort of 39 subjects consisting of children born to mothers who suffered from obesity or obesity with gestational diabetes during pregnancy and healthy controls. We performed longitudinal measurements throughout the first year of life (0, 6 and 12 months; total N = 92) using Illumina Infinium MethylationEPIC BeadChip arrays to profile more than 770,000 CpG sites. The design allowed us to carry out both cross-sectional and longitudinal analyses in order to derive DNA methylation alterations associated with developmental and pathological-related epigenomics., [Results]: We have identified abundant DNA methylation alterations during child development from birth to 6 months and, to a lesser extent, until 12 months of age. At the same time, using cross-sectional analyses, we have identified DNA methylation biomarkers that discriminate children born to mothers who suffered from obesity or obesity with gestational diabetes during pregnancy compared to their healthy counterparts. Moreover, our longitudinal design allowed us to determine that these alterations are at least maintained during the first year of life. In addition, gene enrichment analyses revealed that these DNA methylation alterations are associated with regions and genes related to feeding behaviour, appetite, metabolism and cell signalling., [Conclusions]: Our results support the existence of an intrauterine-mediated maternal obesity effect with an impact on the childhood methylome and possible functional implications., This work was supported by: the Spanish Association Against Cancer (grant number PROYE18061FERN to M.F.F.), the Asturias Government (PCTI) cofounding 2018-2022/FEDER (grant number IDI/2018/146 to M.F.F.), the Fundación General CSIC (grant number 0348_CIE_6_E to M.F.F.), the Institute of Health Carlos III (Plan Nacional de I+D+I) cofounding FEDER (grant numbers PI18/01527 and PI21/01067 to M.F.F. and A.F.F.; grant numbers PI17/01517 and PI20/00269 to E.L.), and the Spanish Ministry of Science and Innovation (grant number SGL2021-03-039/40 to M.F.F.) cofounding NextGenerationEU. J.R.T. is supported by a Juan de la Cierva fellowship from the Spanish Ministry of Science and Innovation (grant number IJC2018-36825-I). J.J.A.L. is supported by the Spanish Association Against Cancer (grant number PRDAS21642ALBA). R.F.P. and D.B.R. are supported by the Severo Ochoa program (grant numbers BP17-114 and BP20-186). We also acknowledge support from the Institute of Oncology of Asturias (IUOPA, supported by Obra Social Cajastur Liberbank, Spain), the Health Research Institute of Asturias (ISPA-FINBA), the Health Research Institute INCLIVA and the Biomedical Research Networking Center on Rare Diseases (CIBERER-ISCIII)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Maternal obesity and gestational diabetes reprogram the methylome of offspring beyond birth by inducing epigenetic signatures in metabolic and developmental pathways

  • Alba-Linares, Juan J.
  • Pérez, Raúl F.
  • Tejedor, Juan Ramón
  • Bastante-Rodríguez, David
  • Ponce-Zanon, Francisco
  • García-Carbonell, Nuria
  • Gómez-Zafra, Rafael
  • Fernández, Agustín F.
  • Fraga, Mario F.
  • Lurbe, Empar
This work was supported by: the Spanish Association Against Cancer (Grant number PROYE18061FERN to M.F.F.), the Asturias Government (PCTI) cofounding 2018–2022/FEDER (Grant number IDI/2018/146 to M.F.F.), the Fundación General CSIC (Grant number 0348_CIE_6_E to M.F.F.), the Institute of Health Carlos III (Plan Nacional de I + D + I) cofounding FEDER (Grant numbers PI18/01527 and PI21/01067 to M.F.F. and A.F.F.; Grant numbers PI17/01517 and PI20/00269 to E.L.), and the Spanish Ministry of Science and Innovation (Grant number SGL2021-03-039/40 to M.F.F.) cofounding NextGenerationEU. J.R.T. is supported by a Juan de la Cierva fellowship from the Spanish Ministry of Science and Innovation (Grant number IJC2018-36825-I). J.J.A.L. is supported by the Spanish Association Against Cancer (Grant number PRDAS21642ALBA). R.F.P. and D.B.R. are supported by the Severo Ochoa program (Grant numbers BP17-114 and BP20-186). We also acknowledge support from the Institute of Oncology of Asturias (IUOPA, supported by Obra Social Cajastur Liberbank, Spain), the Health Research Institute of Asturias (ISPA-FINBA), the Health Research Institute INCLIVA and the Biomedical Research Networking Center on Rare Diseases (CIBERER-ISCIII)., Peer reviewed